User profiles for "author:Michele Tameris"
 | Michele TamerisSATVI University of Cape Town Verified email at uct.ac.za Cited by 7155 |
[HTML][HTML] Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial
MD Tameris, M Hatherill, BS Landry, TJ Scriba… - The Lancet, 2013 - thelancet.com
Background BCG vaccination provides incomplete protection against tuberculosis in infants.
A new vaccine, modified Vaccinia Ankara virus expressing antigen 85A (MVA85A), was …
A new vaccine, modified Vaccinia Ankara virus expressing antigen 85A (MVA85A), was …
[HTML][HTML] Efficacy of NVX-CoV2373 Covid-19 vaccine against the B. 1.351 variant
V Shinde, S Bhikha, Z Hoosain, M Archary… - … England Journal of …, 2021 - Mass Medical Soc
Background The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) variants threatens progress toward control of the coronavirus disease 2019 (Covid …
CoV-2) variants threatens progress toward control of the coronavirus disease 2019 (Covid …
[HTML][HTML] Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis
DR Tait, M Hatherill, O Van Der Meeren… - … England Journal of …, 2019 - Mass Medical Soc
Background Results of an earlier analysis of a trial of the M72/AS01E candidate vaccine
against Mycobacterium tuberculosis showed that in infected adults, the vaccine provided …
against Mycobacterium tuberculosis showed that in infected adults, the vaccine provided …
[HTML][HTML] Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis
O Van Der Meeren, M Hatherill, V Nduba… - … England Journal of …, 2018 - Mass Medical Soc
Background A vaccine to interrupt the transmission of tuberculosis is needed. Methods We
conducted a randomized, double-blind, placebo-controlled, phase 2b trial of the M72/AS01E …
conducted a randomized, double-blind, placebo-controlled, phase 2b trial of the M72/AS01E …
The Novel Tuberculosis Vaccine, AERAS-402, Induces Robust and Polyfunctional CD4+ and CD8+ T Cells in Adults
B Abel, M Tameris, N Mansoor… - American journal of …, 2010 - atsjournals.org
Rationale: AERAS-402 is a novel tuberculosis vaccine designed to boost immunity primed
by bacillus Calmette-Guérin (BCG), the only licensed vaccine. Objectives: We investigated …
by bacillus Calmette-Guérin (BCG), the only licensed vaccine. Objectives: We investigated …
[HTML][HTML] T-cell activation is an immune correlate of risk in BCG vaccinated infants
HA Fletcher, MA Snowden, B Landry, W Rida… - Nature …, 2016 - nature.com
Vaccines to protect against tuberculosis (TB) are urgently needed. We performed a case–
control analysis to identify immune correlates of TB disease risk in Bacille Calmette–Guerin …
control analysis to identify immune correlates of TB disease risk in Bacille Calmette–Guerin …
Modified vaccinia Ankara‐expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells
Abstract Modified vaccinia Ankara‐expressing Ag85A (MVA85A) is a new tuberculosis (TB)
vaccine aimed at enhancing immunity induced by BCG. We investigated the safety and …
vaccine aimed at enhancing immunity induced by BCG. We investigated the safety and …
First-in-human trial of the post-exposure tuberculosis vaccine H56: IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults
AKK Luabeya, BMN Kagina, MD Tameris… - Vaccine, 2015 - Elsevier
Background H56: IC31 is a candidate tuberculosis vaccine comprising a fusion protein of
Ag85B, ESAT-6 and Rv2660c, formulated in IC31 adjuvant. This first-in-human, open label …
Ag85B, ESAT-6 and Rv2660c, formulated in IC31 adjuvant. This first-in-human, open label …
Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa
T Hawkridge, TJ Scriba, S Gelderbloem… - The Journal of …, 2008 - academic.oup.com
Background. The efficacy of bacille Calmette-Guérin (BCG) may be enhanced by
heterologous vaccination strategies that boost the BCG-primed immune response. One …
heterologous vaccination strategies that boost the BCG-primed immune response. One …
[HTML][HTML] Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial
TJ Scriba, A Fiore-Gartland… - The Lancet Infectious …, 2021 - thelancet.com
Background Targeted preventive therapy for individuals at highest risk of incident
tuberculosis might impact the epidemic by interrupting transmission. We tested performance …
tuberculosis might impact the epidemic by interrupting transmission. We tested performance …